Time New York: Sun 22 Oct 18:45 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Mallinckrodt to Pay $35M for Controlled Substances Probe

Zacks

Mallinckrodt plc MNK recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York.

The agreement will settle the previously disclosed investigations relating to the company's suspicious order monitoring program, reporting, record keeping and security measures related to manufacturing and distribution of controlled substances.

We remind investors that the company received subpoenas from the DEA requesting production of documents relating to its suspicious order monitoring program for controlled substances in Nov 2011 and Oct 2012. The USAO was investigating the possibility of Mallinckrodt failing to report suspicious orders of controlled substances during 2006-2011 in violation of the Controlled Substances Act and its related regulations. The USAO was also investigating whether the company failed to maintain appropriate records and security measures with respect to manufacturing of certain controlled substances at its Hobart facility during 2012-2013.

As part of the settlement, Mallinckrodt will pay $35 million to resolve all potential claims. This, however, will not impact the company’s financials.


Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to persistent challenging conditions. The company also sold its Intrathecal Therapy business to focus on its key areas. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Weakness in shares persists as the company’s shares have lost 13.6% year to date compared with the Zacks categorized Medical – Generics Drugs industry’s decline of 2.5%.

Earlier, Endo International plc ENDP announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June over reported misuse. In March, the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted in the ratio of 18 to 8 and consented that reformulated Opana ER did not outweigh public health risks. The FDA asked the Advisory Committees to discuss the pre- and post-marketing data about the abuse of Opana ER as well as the product's overall risk-benefit profile. The abuse of generic oxymorphone ER and oxymorphone immediate-release (IR) products were to be evaluated as well. Few members stated that the benefits are now overshadowed by the continuing public health concerns around the product's misuse, abuse and diversion.

Zacks Rank and Stocks to Consider

Mallinckrodt currently carries a Zacks Rank #4 (Sell). A couple of better-ranked stocks in the sector are Enzo Biochem, Inc. ENZ and AstraZeneca plc AZN. Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Shares of AstraZeneca have rallied 21.6% so far this year. Also, its earnings estimates for 2017 moved up 0.5%, while the same for 2018 climbed 3.3% in the last 60 days. Its earnings performance has been pretty impressive as well, with consistent positive surprises. The company’s average earnings beat for the last four quarters is 142.6%.

Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 30 days. The company delivered positive earnings surprises in all of the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 61.1% year to date.

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.